Zepbound on Hims & Hers is now part of an agreement Eli Lilly and the telehealth company announced on November 6, 2026: patients prescribed by a licensed Hims & Hers provider can get Zepbound (tirzepatide) injections from $299 a month and Foundayo (orforglipron) tablets from $149 a month without leaving the platform. The prices match what any self-pay patient pays Lilly, and Hims & Hers has committed never to sell compounded copies of Lilly’s GLP-1 medicines. The deal moves the largest US weight-loss telehealth brand firmly onto branded drugs and gives Lilly another front door to cash-paying patients.
Key takeaways on Zepbound on Hims & Hers
- Hims & Hers providers can now prescribe and fulfil Zepbound and Foundayo directly; before the deal, these patients were redirected to Lilly’s own LillyDirect channel.
- Self-pay pricing starts at $299 a month for Zepbound and $149 a month for Foundayo, the same as Lilly’s direct prices.
- Medicines ship to the patient’s home, bundled with Hims & Hers check-ins, nutrition guidance and 24/7 care team access.
- Hims & Hers says it has never offered compounded copies of Lilly’s GLP-1s and will not in future.
- Novo Nordisk struck a similar deal with Hims & Hers earlier in 2026 for Wegovy injection and tablets.
- The release does not give a start date, per-dose prices or which Zepbound presentation (vial or pen) will be offered.
How ordering will work for patients
The flow is the standard telehealth model. A patient completes an online consultation, a licensed clinician on the platform decides whether a prescription is appropriate, and the drug is shipped home. Lilly stresses that providers keep independent clinical judgement, which matters because both drugs are prescription-only and carry boxed warnings about thyroid C-cell tumours. Neither is for people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Other serious risks on the labels include pancreatitis, gallbladder problems, dehydration and low blood sugar.
| Zepbound (tirzepatide) | Foundayo (orforglipron) | |
|---|---|---|
| Form | Injection | Oral tablet |
| Dosing frequency | Once weekly | Once daily |
| Label strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg |
| Self-pay price on Hims & Hers | From $299/month | From $149/month |
| Mechanism | GIP and GLP-1 receptor agonist | Small-molecule GLP-1 receptor agonist |
One practical point for searchers: the deal does not make Zepbound cheaper than buying it from Lilly directly. Its value is convenience, with the prescription, pharmacy and follow-up inside one app. Patients with insurance coverage for obesity medicines may still pay less through their plan.
Why Lilly is doing this now
Lilly USA president Ilya Yuffa framed the deal as “meeting patients where they already are”, noting that millions of people already use Hims & Hers for care. The commercial logic is plain. The cash-pay obesity market is now a large share of GLP-1 demand, and telehealth platforms own the customer relationship. By offering branded drugs at list self-pay prices, Lilly captures patients who might otherwise drift toward cheaper compounded products.
The deal also sharpens Lilly’s fight with Novo Nordisk, which is already on the platform. Third-quarter figures show where the two stand.
| Q3 2026 product | Sales | Change |
|---|---|---|
| Zepbound (Lilly, global) | $5.35 billion | +49% |
| Wegovy injection (Novo) | About $3.0 billion | -2% |
| Wegovy pill (Novo) | $813 million | Launch year |
| Foundayo (Lilly) | $184 million | Launch year |
By our calculation, Foundayo’s sales were less than a quarter of the Wegovy pill’s in the quarter. A low $149 entry price on a high-traffic platform is one way to close that gap in the oral market, where Lilly is the later entrant.
What it means for compounded GLP-1s
Hims & Hers built its weight-loss business partly on compounded semaglutide, and its earlier alliance with Novo ended badly, with Novo later taking legal action over compounded versions of its drugs. Lining up both big GLP-1 makers suggests the company is steering its core obesity offer toward FDA-approved products. Lilly’s release says Hims & Hers has never offered compounded copies of Lilly’s GLP-1s and will not do so. Regulators worldwide are also tightening rules on compounded weight-loss drugs; see our report on South Africa’s planned rules.
Market context: digital obesity care
The deal sits where drug sales meet digital care. According to Acumen Research and Consulting, the global digital health for obesity market was worth USD 48.1 billion in 2023 and is projected to reach USD 276.5 billion by 2032, growing at a compound annual rate of 21.7%. Acumen found that services held the largest share and North America led the market, which is exactly the segment a telehealth-plus-medicine model like this one targets.
Open questions
- Launch date: neither company has said when the option goes live.
- Dose pricing: only starting prices were disclosed; higher maintenance doses usually cost more on self-pay programmes.
- Insurance: the release covers self-pay only. It is unclear whether insured patients can use coverage through the platform.
- New safety labelling: the FDA recently ordered a class-wide eye-risk warning for GLP-1 drugs; read our explainer on the GLP-1 NAION warning.
More drug coverage is in our Pharmaceutical section.
FAQ
Can I get Zepbound through Hims & Hers?
Yes, under the Lilly agreement, if a licensed provider on the platform decides it is appropriate for you. The companies have not announced the exact start date.
How much does Zepbound cost on Hims & Hers?
Self-pay pricing starts at $299 a month, the same as Lilly’s direct self-pay price. Foundayo starts at $149 a month.
Does Hims & Hers sell compounded tirzepatide?
No. According to the joint release, Hims & Hers has never offered compounded copies of Lilly’s GLP-1 medicines and has committed not to in the future.
Is Foundayo the same as Zepbound?
No. Foundayo (orforglipron) is a once-daily pill that acts on the GLP-1 receptor. Zepbound (tirzepatide) is a weekly injection that acts on both GIP and GLP-1 receptors.
Sources: Lilly and Hims & Hers press release (November 6, 2026); pharmaphorum. Market data: Acumen Research and Consulting. This article is for information only and is not medical or investment advice. Last updated: November 12, 2026.

